ArticleBMJ open2026
Cardiovascular events and mortality after breast cancer diagnosis: multistate models in a nationwide cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the progression of newly diagnosed breast cancer patients towards cardioembolic disorders (CDs) and ischaemic or structural heart disease (ISH) within a multistate framework that includes death as an absorbing state, in order to evaluate long-term cardiovascular burden and to examine whether the observed patterns may reflect short-term acute events or longer-term effects potentially associated with treatment. CD and ISH occurrences following breast cancer treatment may have different underlying biological mechanisms, potentially leading to different survival patterns across patient groups defined by breast cancer characteristics, and we sought to explore this.
designTwo continuous-time multistate Markov models described patients' transitions among three states: time of breast cancer diagnosis, first occurrence of CD or ISH, and death, depending on patients' molecular subtype, tumour stage, age and radiation treatment status.
participantsAltogether 36 778 patients from the Norwegian Cancer Registry, linked with information on cardiovascular events from the Norwegian Patient Registry, diagnosed earliest in 2006, followed until their first cardiovascular event and/or death or throughout 2020.
resultsHR-/HER2- patients had the highest HR for a first CD event compared with HR+/HER2- patients (HR 1.51, 95% CI 1.39 to 1.65), with no significant differences observed between the remaining groups. For first ISH event, HR-/HER2+, HR+/HER2+ and HR-/HER2- patients had HRs of 1.91 (95% CI 1.61 to 2.27), 1.64 (95% CI 1.43 to 1.88) and 1.56 (95% CI 1.44 to 1.69), respectively, compared with HR+/HER2- patients.
conclusionsLong-term cardiovascular burden for patients with breast cancer may be more strongly influenced by chronic vascular and myocardial damage, likely driven by treatment-related cardiotoxicity and cumulative exposure compared with acute thromboembolic mechanisms. A multistate Markov modelling approach proved valuable for capturing the dynamics for patients to move between the states breast cancer diagnosis, CD or ISH event and death, and may guide more tailored follow-up and use of cardioprotective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.